p.107 抽出テキスト

Recommendation Table 9 for baseline risk assessment and monitoring during fluoropyrimidine therapy Baseline CV risk assessment and evaluation including BP measurement, ECG, lipid profile, HbA1c measurement, and SCORE2/SCORE2- OP or equivalent is recommended before starting fluoropyrimidines. I C

A baseline echocardiogram is recommended in patients with a history of symptomatic CVD before starting fluoropyrimidines. I C

Recommendation Table 10 for baseline risk assessment and monitoring during VEGFi BP monitoring

BP measurement is recommended for patients treated with VEGFi, bevacizumab, or ramucirumab at every clinical visit. I C

Daily home monitoring of BP for patients treated with VEGFi during the first cycle, after each increase of VEGFi dose, and every 2–3 weeks thereafter is recommended. I C ECG monitoring In patients treated with VEGFi at moderate or high risk of QTc prolongation, QTc monitoring is recommended monthly during the first 3 months and every 3–6 months thereafter. I C Echocardiography

Baseline echocardiography is recommended in high- and very high-risk patients treated with VEGFi or bevacizumab. I C

Recommendation Table 11 for baseline risk assessment and monitoring during second- and third-generation BCR-ABL tyrosine kinase inhibitors

Baseline CV risk assessment is recommended in patients who require second- or third-generation BCR-ABL TKI. I C

In patients treated with nilotinib or ponatinib, CV risk assessment is recommended every 3 months during the first year and every 6–12 months thereafter. I C

Baseline echocardiography is recommended in patients scheduled to receive dasatinib. I C

Recommendation Table 12 for baseline risk assessment and monitoring Bruton tyrosine kinase inhibitor therapy BP monitoring and management

BP measurement is recommended for patients treated with BTK inhibitors at every clinical visit. I B

Echocardiography

Baseline echocardiography is recommended in high-risk patients scheduled to receive BTK inhibitors. I C

TTE is recommended in all patients who develop AF during BTK inhibitor therapy. I C

AF

Opportunistic screening for AF by pulse-taking or ECG rhythm strip is recommended at every clinical visit during BTK inhibitor therapy. I C

Recommendation Table 13 for baseline risk assessment and monitoring during multiple myeloma therapies BP monitoring

BP measurement is recommended for patients treated with PI at every clinical visit. I C

Cardiac serum biomarkers

Measurement of NP is recommended prior to PI in high- and very high-risk patients. I C

NP and cTn measurements are recommended at baseline and every 3–6 months in patients with AL-CA. I B

TTE

Baseline echocardiography, including assessment for AL-CA, is recommended in all patients with MM scheduled to receive PI. I C

Continued Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026